Published in J Clin Oncol on January 31, 2011
Carboplatin in clinical stage I seminoma: too much and too little at the same time. J Clin Oncol (2011) 2.07
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol (2012) 1.44
Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma. Br J Cancer (2013) 0.85
Treatment preferences in stage IA and IB testicular seminoma: multicenter study of Anatolian Society of Medical Oncology. World J Urol (2015) 0.82
Adjuvant radiotherapy for synchronous bilateral testicular seminoma: a case report and a review of the pertinent literature. Case Rep Urol (2013) 0.81
Carboplatin dosing for adult Japanese patients. Nagoya J Med Sci (2014) 0.80
Controversies in the management of clinical stage I testicular seminoma. Cent European J Urol (2016) 0.80
Testicular cancer: Optimal management of stage I seminoma in 2015. Nat Rev Urol (2015) 0.78
Surveillance policy for Japanese patients with stage I testicular germ cell cancer in the multi-detector computed tomography era. Int J Clin Oncol (2015) 0.78
Chemotherapy curable malignancies and cancer stem cells: a biological review and hypothesis. BMC Cancer (2016) 0.77
Carboplatin does not prevent contralateral testicular tumors in patients with seminoma. J Clin Oncol (2011) 0.77
Two cycles of adjuvant carboplatin in stage I seminoma: 8-year experience by the Hellenic Cooperative Oncology Group (HECOG). World J Urol (2015) 0.77
Cost analysis of adjuvant management strategies in early stage (stage I) testicular seminoma. Res Rep Urol (2015) 0.76
Testicular seminoma clinical stage 1: treatment outcome on a routine care level. J Cancer Res Clin Oncol (2016) 0.76
The diagnostic yield of fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography in recurrent testicular seminoma. Urol Ann (2017) 0.75
Off-label use of targeted therapies in oncology. World J Clin Oncol (2016) 0.75
Advances in the treatment of testicular cancer. Transl Androl Urol (2015) 0.75
Management of stage I testicular germ cell tumours. Nat Rev Urol (2016) 0.75
Impact of Bep or Carboplatin Chemotherapy on Testicular Function and Sperm Nucleus of Subjects with Testicular Germ Cell Tumor. Front Pharmacol (2016) 0.75
Adjuvant radiation therapy in stage I seminoma: 20 years of oncologic results. Oncotarget (2016) 0.75
Long-term outcomes following post-operative radiotherapy for Stage I/II testicular seminoma - an Australasian single-institution experience. J Med Radiat Sci (2016) 0.75
Novel therapies in genitourinary cancer: an update. J Hematol Oncol (2008) 0.75
Exploration of the treatment challenges in men with intellectual difficulties and testicular cancer as seen in Down syndrome: single centre experience. BMC Med (2015) 0.75
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med (2006) 26.37
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet (2007) 9.24
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet (2011) 8.81
Adjuvant docetaxel for node-positive breast cancer. N Engl J Med (2005) 8.00
U.K. Controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med (2005) 7.58
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (2009) 7.44
Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 5.18
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol (2009) 4.34
Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09). Lancet Oncol (2013) 3.85
Studies comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manage (2011) 3.44
The randomized trials of breast cancer screening: what have we learned? Radiol Clin North Am (2004) 3.06
Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst (2004) 2.79
The clinical features and management of testicular germ cell tumours in patients aged 60 years and older. BJU Int (2011) 2.78
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet (2009) 2.75
Open letter to UK Prime Minister David Cameron and Health Secretary Andrew Lansley on safety of medicines. Lancet (2011) 2.64
Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer (2007) 2.55
Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983. J Clin Oncol (2012) 2.36
Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol (2003) 2.35
Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. NMR Biomed (2002) 2.24
Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol (2007) 2.24
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol (2012) 2.14
Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol (2003) 2.09
Which domains should be included in a cancer pain classification system? Analyses of longitudinal data. Pain (2012) 2.07
Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up. J Natl Cancer Inst (2011) 1.91
Acupuncture and counselling for depression in primary care: a randomised controlled trial. PLoS Med (2013) 1.90
Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol (2005) 1.83
Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol (2007) 1.80
Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist (2008) 1.77
Randomized trial of exercise therapy in women treated for breast cancer. J Clin Oncol (2007) 1.77
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol (2012) 1.76
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group. J Clin Oncol (2005) 1.69
Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res (2006) 1.65
Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol (2010) 1.58
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol (2012) 1.55
Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol (2002) 1.47
Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clin Cancer Res (2012) 1.42
Improving adherence to guidelines for hypertension drug prescribing: cluster-randomized controlled trial of general versus patient-specific recommendations. Am J Manag Care (2005) 1.40
First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC series. Eur J Cancer (2010) 1.40
Pathological findings after primary chemotherapy in patients undergoing simultaneous orchidectomy and retroperitoneal lymph node dissection for advanced germ cell tumours. BJU Int (2012) 1.39
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol (2007) 1.37
Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol (2010) 1.36
Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review. Pain (2011) 1.22
Management of brain metastases in patients with high-risk gestational trophoblastic tumors. J Reprod Med (2002) 1.13
Using community-based participatory research to ameliorate cancer disparities. Health Soc Work (2010) 1.12
Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology (2007) 1.08
Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol (2006) 1.07
Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519). J Clin Oncol (2010) 1.06
Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience. Gynecol Oncol (2010) 1.02
Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clin Cancer Res (2004) 1.01
Placental site trophoblastic tumour: clinical features and management. Gynecol Oncol (2005) 1.01
Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. J Natl Cancer Inst (2004) 0.99
Aberrant p16 methylation is a biomarker for tobacco exposure in cervical squamous cell carcinogenesis. Am J Obstet Gynecol (2004) 0.97
Do corticosteroids provide analgesic effects in cancer patients? A systematic literature review. J Pain Symptom Manage (2012) 0.96
Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction. Gynecol Oncol (2007) 0.96
Screening for breast cancer. Surg Oncol Clin N Am (2005) 0.95
Are emergency admissions in palliative cancer care always necessary? Results from a descriptive study. BMJ Open (2013) 0.95
Which variables are associated with pain intensity and treatment response in advanced cancer patients?--Implications for a future classification system for cancer pain. Eur J Pain (2010) 0.94
Evidence-based oncology in cancer treatment reviews. Cancer Treat Rev (2003) 0.94
Progress in the management of gynecologic cancer: consensus summary statement. J Clin Oncol (2003) 0.94
Can we now agree to use the same definition to measure response according to CA-125? J Clin Oncol (2004) 0.94
Exercise therapy in women who have had breast cancer: design of the Sheffield women's exercise and well-being project. Health Educ Res (2004) 0.93
Pulmonary function in long-term survivors of testicular cancer. J Clin Oncol (2009) 0.93
Candidate genes for testicular cancer evaluated by in situ protein expression analyses on tissue microarrays. Neoplasia (2003) 0.92
The Edmonton Classification System for Cancer Pain: comparison of pain classification features and pain intensity across diverse palliative care settings in eight countries. J Palliat Med (2013) 0.92
Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer. Clin Cancer Res (2010) 0.91
Dynamic MRI for imaging tumor microvasculature: comparison of susceptibility and relaxivity techniques in pelvic tumors. J Magn Reson Imaging (2007) 0.89
Reducing the global breast cancer burden: the importance of patterns of care research. Clin Breast Cancer (2005) 0.89
Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. Clin Cancer Res (2012) 0.89
Neuropathic cancer pain: prevalence, severity, analgesics and impact from the European Palliative Care Research Collaborative-Computerised Symptom Assessment study. Palliat Med (2012) 0.88
nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial. Breast Cancer Res Treat (2009) 0.88
The causes and treatment of bone loss associated with carcinoma of the breast. Cancer Treat Rev (2005) 0.88
A joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancer. Crit Rev Oncol Hematol (2006) 0.88
Recombinant factor VIIa in the management of pulmonary hemorrhage associated with metastatic choriocarcinoma. J Clin Oncol (2008) 0.88
Follow-up care for young adult survivors of cancer: lessons from pediatrics. J Cancer Surviv (2007) 0.88
Predicting gestational trophoblastic neoplasia (GTN): is urine hCG the answer? Gynecol Oncol (2011) 0.87
Determinants of adherence to exercise in women treated for breast cancer. Eur J Oncol Nurs (2007) 0.87
Ovarian failure following cancer treatment: current management and quality of life. Hum Reprod (2008) 0.86
Delay in the diagnosis of testicular tumours - changes over the past 18 years. Br J Gen Pract (2004) 0.86
Adjuvant use of anastrozole in breast cancer. J Clin Oncol (2004) 0.86
A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors. Invest New Drugs (2013) 0.86
Patient recruitment into a randomised controlled trial of supervised exercise therapy in sedentary women treated for breast cancer. Contemp Clin Trials (2007) 0.86
What does the answer mean? A qualitative study of how palliative cancer patients interpret and respond to the Edmonton Symptom Assessment System. Palliat Med (2011) 0.85